<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB12216</drugbank-id>
  <name>Bergapten</name>
  <description>Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).</description>
  <cas-number>484-20-8</cas-number>
  <unii>4FVK84C92X</unii>
  <average-mass>216.192</average-mass>
  <monoisotopic-mass>216.042258738</monoisotopic-mass>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 5-methoxypsoralens. These are psoralens containing a methoxy group attached at the C5 position of the psoralen group.</description>
    <direct-parent>5-methoxypsoralens</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Phenylpropanoids and polyketides</superclass>
    <class>Coumarins and derivatives</class>
    <subclass>Furanocoumarins</subclass>
    <alternative-parent>1-benzopyrans</alternative-parent>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Anisoles</alternative-parent>
    <alternative-parent>Benzofurans</alternative-parent>
    <alternative-parent>Furans</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Lactones</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Pyranones and derivatives</alternative-parent>
    <substituent>1-benzopyran</substituent>
    <substituent>5-methoxypsoralen</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzofuran</substituent>
    <substituent>Benzopyran</substituent>
    <substituent>Ether</substituent>
    <substituent>Furan</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Lactone</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Pyran</substituent>
    <substituent>Pyranone</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">5 methoxypsoralen</synonym>
    <synonym language="english" coder="">5-methoxypsoralen</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Antipsoriatics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antipsoriatics for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzopyrans</category>
      <mesh-id>D001578</mesh-id>
    </category>
    <category>
      <category>Coumarins</category>
      <mesh-id>D003374</mesh-id>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Furocoumarins</category>
      <mesh-id>D011564</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Photosensitizing Agents</category>
      <mesh-id>D017319</mesh-id>
    </category>
    <category>
      <category>Psoralens for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pyrans</category>
      <mesh-id>D011714</mesh-id>
    </category>
    <category>
      <category>Radiation-Sensitizing Agents</category>
      <mesh-id>D011838</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="D05BA03">
      <level code="D05BA">Psoralens for systemic use</level>
      <level code="D05B">ANTIPSORIATICS FOR SYSTEMIC USE</level>
      <level code="D05">ANTIPSORIATICS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00707</drugbank-id>
      <name>Porfimer sodium</name>
      <description>Bergapten may increase the photosensitizing activities of Porfimer sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00460</drugbank-id>
      <name>Verteporfin</name>
      <description>Bergapten may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The serum concentration of the active metabolites of Bergapten can be increased when Bergapten is used in combination with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be increased when used in combination with Bergapten.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.12</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.48e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-methoxy-7H-furo[3,2-g]chromen-7-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>bergapten</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>216.192</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>216.042258738</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC1=C2C=CC(=O)OC2=CC2=C1C=CO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H8O4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BGEBZHIAGXMEMV-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>48.67</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>56.85</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>20.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>18293</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2355</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828496</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C01557</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2265</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50067880</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Bergapten</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL24171</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>